First-in-Class CD146-Targeting Peptide Probes for Noninvasive PET Imaging of Melanoma

Q D Zhang; Xiaoyi Guo; Siqi Hao; Qian Chen; Yang Jiang; Yu Zhang; Huanhuan Cao; Hua Zhu; Zhi Yang; Teli Liu

doi:10.1021/acs.molpharmaceut.6c00184

July 7, 2026Molecular Pharmaceutics

First-in-Class CD146-Targeting Peptide Probes for Noninvasive PET Imaging of Melanoma

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate a novel peptide probe for noninvasive imaging of melanoma that expresses CD146.
Development of Ga]Ga-DOTA-P1 as a peptide probe for PET imaging.
Focus on high-contrast imaging for prompt identification of CD146-expressing tumors.
Assessment of patient stratification for targeted therapies.
Ga]Ga-DOTA-P1 showed significant improvements in imaging contrast for CD146-expressing melanoma.
Demonstrated practicality for noninvasive assessment in patient stratification.
Indicates the potential for enhancing targeted therapeutic approaches in melanoma.

Implication

Demonstrates noninvasive PET imaging for melanoma using CD146-targeting probes, indicating new strategies for treatment evaluation.

Abstract

Ga]Ga-DOTA-P1 as a rapid, high-contrast imaging tool for CD146-expressing malignancies, offering a practical strategy for noninvasive patient stratification in the era of targeted CD146 therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a4f3c8a2b81a944af575d72 https://doi.org/10.1021/acs.molpharmaceut.6c00184

View at Publisher

Ask AI

Bookmark

Share

First-in-Class CD146-Targeting Peptide Probes for Noninvasive PET Imaging of Melanoma

Key Points

Implication

Abstract

Discussion

Cite This Study

First-in-Class CD146-Targeting Peptide Probes for Noninvasive PET Imaging of Melanoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading